1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
E-therapeutics Plc

E-therapeutics Plc

ETXPF
E-therapeutics PlcUS flagOther OTC
0.13
USD
- -
- -
75.96MMarket Cap
E-therapeutics Plc
ETXPF
(Other OTC)

Recent

price

0.13

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.04
-0.03
-0.03
-0.04
-0.02
-0.03
-0.02
-0.03
-0.03
-0.05
-0.02
-0.01
-0.01
-0.01
-0.02
-0.02
Basic EPS, GAAP
-0.05
-0.03
-0.03
-0.03
-0.03
-0.03
-0.02
-0.04
-0.04
-0.04
-0.02
-0.01
-0.01
-0.01
-0.02
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.04
-0.07
-0.09
-0.12
-0.08
-0.11
-0.08
-0.1
-0.14
-0.18
-0.2
-0.22
-0.23
-0.17
-0.15
-0.15
Book Value per Share
0.05
0.01
0.04
- -
0.11
0.07
0.17
0.14
0.1
0.06
0.04
0.02
0.02
0.04
0.06
0.06
Tangible Book Value per Share
52
56
60
66
131
138
254
264
264
267
268
269
269
373
488
537
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-2,695.31
-3,007.46
- -
- -
- -
- -
- -
- -
- -
- -
- -
-11,622.73
-633.33
-1,414.83
-2,005.66
-2,155.58
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-2
-2
-2
-3
-4
-5
-8
-9
-13
-5
-4
-2
-4
-8
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-3,071.88
-2,307.46
- -
- -
- -
- -
- -
- -
- -
- -
- -
-9,088.64
-514.69
-1,162.15
-1,691.19
-1,741.89
Profit Margin (%)
2
1
3
1
14
10
44
36
28
16
11
7
4
14
27
32
Working Capital
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
2
1
2
- -
15
11
45
37
28
16
11
7
5
14
28
33
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.17%
51.36%
19.18%
Free Cash Flow
20.17%
31.06%
-6.17%
Net Income, GAAP
18.98%
22.36%
2.57%
Sales/Revenue/Turnover
- -
- -
-0.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.02
2023
- -
- -
- -
- -
-0.02
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Roivant Sciences Ltd. (ROIVW)
Alpha Cognition Inc. (ACOGF)
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV)
Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
OncoSec Medical Incorporated (ONCSQ)
Business
E-therapeutics Plc (ETXPF) develops RNAi therapeutics targeting novel genes in hepatocytes to treat diseases with high unmet need, leveraging the proprietary HepNet computational platform for target identification, drug design and AI integration; and the GalOmic RNAi platform for potent GalNAc-siRNA constructs that selectively silence disease-associated genes. Core products in its preclinical pipeline include ETX-312 for metabolic dysfunction-associated steatohepatitis (MASH), ETX-407 for dry age-related macular degeneration, ETX-148 for haemophilia and bleeding disorders, ETX-291 for cardiometabolic disease, and ETX-258 in an undisclosed indication, with IND-enabling studies underway for ETX-312 and planned for ETX-407. The company operates in the biotechnology sector focused on cardiometabolic, haematology and ophthalmology indications, primarily targeting patients with liver-mediated diseases via hepatocyte-specific interventions. Founded in 2001 and headquartered in London, UK, with operations expanded to the US East Coast biotech hub. Recent developments encompass a £28.9 million fundraise in April 2024 from M&G Investment Management and Richard Griffiths to advance pipeline assets toward clinical trials and accelerate AI integration into HepNet; delisting from AIM in May 2024 to pursue broader investor bases including potential NASDAQ listing; strategic AWS partnership for AI enhancements; Arcturis collaboration integrating real-world evidence data into HepNet; completion of preclinical proof-of-concept for four GalOmic assets; appointment of Lord David Prior as Chair in May 2024 and Timothy Bretherton as CFO in September 2023; and milestone payment from iTeos collaboration validating computational target discovery.